The use and evaluation of digital biomarkers, objective and quantifiable measures of biology, and health collected through digital devices is growing rapidly. To highlight some of the most promising work in the field, we have compiled a list of the top digital biomarkers papers from the past year. Eligible papers reported on original research that evaluated a digital sensor (e.g., smartphone, wearable sensor, implantable device) in humans and was published in a peer-reviewed journal in 2017. Nominations were solicited from the editorial board of Digital Biomarkers and supplemented by papers the editorial team identified from Web of Science, Google Scholar, and PubMed. The editorial board then selected up to ten papers to be recognized among 28 nominations. Here, we present all of the nominated papers and profile the eight that received the most votes. The top eight papers evaluated 1,290 individuals with digital pills, smartwatches, wearable devices, and electronic inhalers in disease states ranging from dementia to diabetes and from Parkinson disease to pain.
characteristics of the study participants and the impact upon underserved populations. The "digital divide" [9] , the differential access to the internet and related technologies based on economic, geographic, and social factors, is an enormous barrier to the use of digital sensors and telehealth generally [10, 11] . One important study [5] in southern California that sought to empower individuals with uncontrolled hypertension and diabetes by using digital pills to track adherence, wearable sensors, and a mobile application enrolled 109 participants, of whom 46% were Hispanic, 57% had an income of less than USD 20,000, and 52% had a high school education or less. Studies like this will be important to demonstrate the value of these digital sensors for all [11] . Just as the diseases studied were diverse, so too were the digital sensors. Among the sensors evaluated were the following: sensor boxes in the home that passively assess light, temperature, and movement; watches; wearable accelerometers; digital pills that can communicate when they have been ingested; several smartphone applications; pulse oximeters; and smart bracelets. In five of the eight studies, more than one digital tool was evaluated as part of the intervention studied. The result is that large data sets are generated even from small studies (e.g., 9,600 h of activity data from a 20-person study).
The duration of studies is also increasing. Only two of the eight studies were crosssectional, and one lasted 1 year. As most clinical measures in use today are limited to episodic, in-clinic assessments, digital biomarkers are seeking to gather data both inside and outside the clinic. Six of the eight studies, which spanned Asia, Europe, and North America, gathered health data on how people are doing in "real-world" settings. Shining light on how individuals Importantly, the studies are seeking to not only replicate what is currently measured in the clinic, but also generate novel measures of health and disease. Among these novel measures are the time individuals spend lying down. In Huntington disease, a rare genetic disorder, Adams et al. [3] found that ambulatory individuals with the condition who are well enough to come to the clinic spend half their days at home lying down, a previously unknown finding. In addition, digital biomarkers are not only measuring health but predicting it as well. Shah et al. [7] used the data from digital sensors to predict COPD exacerbations. While their results were modest, future efforts will build upon theirs to help prevent disease before it occurs. With recent approval of reimbursement codes for remote monitoring and patient-generated data in the United States, many of the validated novel digital biomarkers now have pathway to make into clinical practice in the near future. Finally, the value of these papers -and thus digital biomarkers -is increasingly recognized. Of the eight top papers published in 2017, five have already been cited by early 2018, and one [8] already has ten citations. We list the profiles of the top eight papers and provide an overview of all the nominated papers ( Table 2) .
Profiles of the Top Eight Digital Biomarkers Papers of 2017
Urwyler et al. [1] Hands free sensors can quantify the erratic daily life of individuals with dementia. This study evaluated the use of passive monitoring systems for identifying activities of daily living in 10 individuals with Alzheimer disease and 10 age-matched controls over 20 consecutive days encompassing 9,600 h of activity data. The passive monitoring system consisted of a series of sensor boxes capable of detecting light, temperature, humidity, movement, and acceleration. Placed at strategic locations around the participants' homes, these sensor boxes distinguished eight activities of daily living including sleeping, grooming, and eating. Visualized activity maps of individuals with dementia demonstrated disorganized behavior and significant heterogeneity. Their lives are fragmented and, in comparison to those without dementia, far less predictable. After 20 days, the sensors could differentiate those with dementia from those without with an accuracy of 95%.
As the authors point out, "[The] functional capability of dementia patients is traditionally assessed using questionnaires in a brief clinical visit. In contrast, sensor-based measurement systems allow to continuously monitor patients in their natural environment." They conclude, "[Sensor-based] recognition systems over the long run can help to make 'aging in place' a possibility for elderly people and patients suffering from dementia."
Silva de Lima et al. [2]
The largest wearable sensor study in Parkinson disease to date has opened the door to a new class of clinical research. A total of 954 participants were recruited across two populations in the Netherlands (n = 304) and in North America (n = 649). Each participant received a Pebble smartwatch which interfaced with the individual's own Android smartphone that supported a companion smartphone application from the Michael J. Fox Foundation that tracked activity, sleep, medication administration, and participant-reported rating of their symptoms such as tremor. Nearly 85% of the participants contributed study data, and compliance was 68%, with participants using the devices for 15-16 h daily. It was encouraging to see that data contribution was not affected by demographics, clinical characteristics, or attitude towards technology. Self-reported depression was associated with lower compliance. By combining the precision of wearable sensors with the statistical power enabled by large sample sizes, studies like this are poised to reveal powerful insights into Parkinson disease. Adams et al. [3] Wearable sensors are unlocking the unexplored world of Huntington and Parkinson disease. Current rating scales for Huntington disease, a rare genetic disorder that causes involuntary movements, dementia, and behavior changes, and Parkinson disease almost ignore how these conditions affect individuals in real-world settings. In this study, 56 individuals with Huntington disease, prodromal Huntington disease (individuals who carry the genetic expansion for the disease but do not have clinical symptoms), Parkinson disease, and controls spent 2 days wearing five accelerometers from MC10 on their chest and four limbs. Sensor-enabled activity monitoring revealed that individuals with Huntington disease spend 50% of their time lying down, substantially more than individuals with Parkinson disease (38%) or those without a movement disorder (34%). Individuals with these movement disorders also had more sleep transitions than controls. This study demonstrated the ability to capture entirely new insights into diseases that are missed during in-clinic assessments, shows the feasibility of assessing individuals with prodromal disease (which will be increasingly important as therapies look to prevent disease), and lays the foundation for longitudinal assessments with sensors with increasing functionality.
Chai et al. [4]
Digital pills could help fight the opioid crisis. Digital pills emit a radiofrequency that can be detected by smartphones to measure ingestion and inform clinicians and others of the dose, timing, and duration of opioid use. An efficient means of tracking the actual use of prescribed medications could give healthcare providers the ability to detect opioid abuse before addiction sets in. To this end, emergency room physicians prescribed oxycodone pills that were encapsulated with a sensor that was activated by gastric chloride and signaled ingestion to a hip-worn receiver to 10 individuals with acute pain due to a bone fracture. After 1 week of monitoring, the digital pill system was 87.3% accurate in detecting ingestion events as measured by pill counts. Eight (80%) rated the system highly acceptable, and 9 (90%) reported willingness to use the digital pills to improve adherence monitoring. Digital pills could reshape monitoring of pain medications and multiple other therapies (e.g., for hepatitis C, tuberculosis, experimental medications) where adherence is critical.
Frias et al. [5]
The damaging effects of hypertension could be offset by a novel method for prescribing medicine. Despite the availability of effective medications, outcomes are marred by poor patient adherence and the lack of patient involvement. This study focused on the effect of an ingestible sensor pill, a wearable activity patch, a mobile application, and a portal for clinicians. In a pilot study, thirteen outpatient clinics in California with large numbers of patients with hypertension and diabetes were randomized to use the digital tools for 4 weeks, 12 weeks, or to no intervention. The patients in the clinics that were randomized to receive the digital tools had a greater reduction in their blood pressure and were more likely to achieve their blood pressure goal. Over 90% of participants thought that the tools were easy to learn and to incorporate into their daily routine and that they improved their health.
Locatelli et al. [6]
A faster, cheaper means of diagnosing movement disorders using wearable sensors is now within reach. Both essential tremor and Parkinson disease can cause tremor, and differentiating between the two can be challenging clinically. In this pilot study of 11 individuals with essential tremor and 16 with Parkinson disease, a wearable sensor with a gyroscope, an accelerometer, and a magnetometer worn on the hand found small differences in tremor frequency and amplitude in the two conditions that differed from tasks performed in the clinic. The decision tree, which was selected as the best classifier for an automatic scoring system of tremor severity, achieved the highest accuracy of 86% and a normalized area under the curve of 0.98.
Shah et al. [7] Lifesaving insights into COPD have been enabled through the marriage of a smartphone application and a portable pulse oximeter. This study aimed to measure the efficacy of a digital health system in predicting COPD exacerbations. The EDGE digital health system employed in this study consisted of an internet-enabled tablet computer, a customized COPD application and digital diary, and a Bluetooth-enabled pulse oximeter. The 12-month study recruited 110 patients to complete data logging sessions consisting of a short digital survey and recording about 2 min of pulse oximeter data. During the study, 27,260 of these sessions were complete over 35,000 monitoring days. Researchers were able to identify a prodromal state consisting of decreased oxygen saturation and increased heat and respiratory rate, which was predictive of an upcoming exacerbation. On the basis of the classifier developed in this work, the authors stated that the prediction of COPD exacerbation episodes with 60-80% sensitivity will result in 36-68% specificity. While still early, this technology allows us to learn how digital biomarkers can be further refined or developed for this widely prevalent condition.
Wen et al. [8]
Can you trust what that commercial sensor is telling you? This study focused on the crossvalidation of ten commercially available wearable sensors. Five healthy participants were outfitted with two smartwatches (Samsung Gear S and Apple Watch), four smart bracelets (FitBit Surge, Jawbone Up3, Mi Band, and TalkBand B2), and four mobile health monitoring applications (Pacer, Ledongli, Samsung S Health applications, and Apple Health applications) over 5 days. The number of steps, distance, activity duration, energy expenditure, sleep duration, and deep sleep duration were compared to each other.
Step count and distance were consistent across all platforms, while other metrics such as energy expenditure, sleep quality, and activity duration lacked consistency. The authors concluded, "[The] current mainstream devices are only reliable in measuring the number of steps and distance. However, the measurement consistencies of activity duration (energy expenditure), sleep quality, and so on, are still inadequate." This validation of step count and distance measurement across major commercially available wearable sensors is a major step forward to wider adoption among researchers as well as clinical practice.
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